Q-omics provides the consensus-scored RNU6-50P profile across patient tissues and cancer cell-line models. RNU6-50P expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, RNU6-50P is differentially expressed in 8, with the highest sampling consensus in BLCA. Additionally, RNU6-50P RNA expression shows 11,574 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BLCA, and UVM as cancer lineages where RNU6-50P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU6-50P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU6-50P survival associations across molecular data types. RNU6-50P RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU6-50P RNA expression–survival associations across cancer types. High RNU6-50P expression shows unfavorable associations in KIRC, UVM and PRAD, but favorable associations in BLCA, SKCM and LUAD. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for RNU6-50P RNA expression.
This table summarizes RNU6-50P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for RNU6-50P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU6-50P shows lower tumor expression in LUSC, THCA and COAD and higher tumor expression in BLCA, KIRC and CHOL. The BLCA box plot shows higher RNU6-50P RNA expression in tumor versus normal tissue (log2 FC = +0.525, t-test p = .003).
This table shows molecular features associated with RNU6-50P in patient tissues and cancer cell lines. In patient samples, RNU6-50P shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
